The
Peruvian molecular test will be rapid, low-cost and portable —unlike the standard one— which will facilitate its delivery to health posts and centers in remote areas of the country, Peruvian neurobiologist Edward Malaga-Trillo reported on Friday.
The scientist —who leads the team dedicated to the project at Lima-based Cayetano Heredia University— explained that, thanks to these characteristics, the Peruvian molecular test will be accessible to the population.
However, he added, it does not mean it will be a home test, as its use will require trained personnel.
In an interview with Andina news agency, Malaga-Trillo recalled that,
after completing the first phase, the test has managed to enter phase II, meaning the clinical validation, the process in which a number of samples are analyzed using a specific protocol.
"The National Health Institute (INS) is in charge of preparing this roadmap, while the General Directorate for Medicines, Supplies and Drugs (Digemid) is responsible for approving the massive use of the test in the Peruvian population," he commented.
Access to molecular testing
The neurobiologist affirmed that he is unaware of the distribution channels for said test, since the team he leads is academic and responsible for developing the prototype. "We do not participate in the production or distribution process," he clarified.
However, he estimates that the test may become accessible through an agreement reached by the State, the Social Health Insurance System (EsSalud) and private clinics.
(END) SMS/RRC/RMB/MVB
Published: 8/21/2020